IDEAYA Biosciences at Cantor Fitzgerald conference: launch and pipeline push
What it means
- What to watch: Policy moves the whole healthcare aisle; trial data moves one company. Knowing which kind of story this is helps.
- How the stock is trading: $IDYA -1.83% in the latest session.
- Timing: It landed during trading hours — the market got to read it live, so the session move beside it may already carry the reaction.
Where the stock stands
$IDYA last changed hands at $31.06, -1.83% on the session, 27% below its 52-week high of $42.68 and 16% above its low of $26.81 — in the lower part of the range. Over the year it has ranged 59% from low to high: a wide band, so a several-percent week is just a week. These are latest-session quotes, not live prices — the live tape is on the $IDYA page.
How much coverage it is getting
Nothing else on $IDYA in the last 30 days: this is the only story Wook has filed, so there is no run to measure it against yet. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
Coming up
$IDYA earnings today. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the next hard numbers on this company are almost here.
What to watch next
For the receipts, the $IDYA page has the full chart, the filings and the valuation model these figures come from. Want the facts without the spin? Read how two or three outlets frame the same story — where they agree is the news, where they differ is the angle. Wook AI, above, can pull live figures and run the numbers on request — how far $IDYA is from its high, or how this week's coverage compares.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $IDYA. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on September 9, 2026. $IDYA has moved -17.06% ($37.45 to $31.06). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.